Logo

BMS Exercises its Option to Develop Exscientia's AI-Designed Drug Candidate

Share this

BMS Exercises its Option to Develop Exscientia's AI-Designed Drug Candidate

Shots:

  • Exscientia to receive $20M as an option exercise fee and is eligible for development milestones along with royalties on any product sales
  • BMS has elected to in-license an Exscientia’s immune-modulating drug candidate & will be responsible for clinical and commercial development of the product
  • In May’21- the companies have expanded the collaboration to accelerate the discovery of drug candidates by using Exscientia’s AI technology for multiple therapeutic areas- including oncology and immunology

  Ref: Exscientia | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions